与HER2-low TNBC相比,HER2-negative TNBC具有更活跃的免疫微环境特征 CD8+效应T细胞、CD4+增殖T细胞和幼稚T细胞在HER2-negative组中似乎更常见。单细胞(T细胞)受体测序(scTCR-seq)结果显示,HER2-negative组具有更丰富的TCR多样性。与HER2-low TNBC相比,HER2-negative TNBC表现出更高的巨噬细胞浸润(主要是M2表型)。GE...
与HER2-low TNBC相比,HER2-negative TNBC具有更活跃的免疫微环境特征 CD8+效应T细胞、CD4+增殖T细胞和幼稚T细胞在HER2-negative组中似乎更常见。单细胞(T细胞)受体测序(scTCR-seq)结果显示,HER2-negative组具有更丰富的TCR多样性。与HER2-low T...
[11]Kurozumi S, Padilla M, Kurosumi M, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99-111. [12]van Mackelenbergh MT, Loibl S, Untch ...
共识声明1.1:在临床实践中,2018年美国临床肿瘤学会和美国病理学会(ASCO/CAP)指南将HER2 IHC 0、1+、2+/ISH- 未扩增的肿瘤定义为“HER2阴性(HER2-negative)”。根据DESTINY-Breast04研究,“HER2低表达(HER2-low)”定义为HER2 IHC 1+...
参考文献: [1]ADC Choices Require Discretion in HER2-Negative MBC.https://www.onclive.com/view/adc-choices-require-discretion-in-her2-negative-mbc [2]https://www.trodelvyhcp.com/ [3]FDA官网.https://www.fda.gov/ [4]2023ESMO会议摘要
[11]Kurozumi S,et al.HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.Breast Cancer Res Treat 2016;158:99–111. [12]Parker JS,et al.Supervised Risk Predictor of Breast Cancer Based on Intrins...
共识声明1.1:在临床实践中,2018年美国临床肿瘤学会和美国病理学会(ASCO/CAP)指南将HER2 IHC 0、1+、2+/ISH- 未扩增的肿瘤定义为“HER2阴性(HER2-negative)”。根据DESTINY-Breast04研究,“HER2低表达(HER2-low)”定义为HER2 IHC 1+、2+伴原位杂交(ISH)未扩增的肿瘤。2018年ASCO/CAP指南指出HER2 IHC 0称为“...
[11]de Moura Leite L.Cesca M.G.Tavares M.C.Santana D.M.Saldanha E.F.Guimarães P.T.et al.HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer.Breast Cancer Res Treat.2021;190:155-163.
[7].Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017;28:2420–8.* 本文由阿斯利康提供支持，仅供医疗专业人士参考 审批编号：CN-106964 有效期至：2023-12-6 *此...
[4]Palmieri, Carlo et al. “Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel ...